Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nasus PharmaNSRX +1.75%14 Net-Net Working Capital is $0.89 as of Jun. 2026. GuruFocus rates NSRX with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 393 Drug Manufacturers companies, Nasus Pharma ranks better than 68.45% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Nasus Pharma's Net-Net Working Capital for the quarter that ended in Jun. 2026 was $0.89.
The industry rank for Nasus Pharma's Net-Net Working Capital or its related term are showing as below:
NSRX's Price-to-Net-Net-Working-Capital is ranked better than 68.45% of 393
companies
in the Drug Manufacturers industry
Industry Median: 8.18
vs NSRX: 4.57
Nasus Pharma (AMEX:NSRX) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Nasus Pharma Net-Net Working Capital Related Terms
Nasus Pharma Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Nasus Pharma's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSRX vs MIRA, SCLX, MDCX: Net-Net Working Capital Comparison
For the Drug Manufacturers - General subindustry, Nasus Pharma's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nasus Pharma Price-to-Net-Net-Working-Capital vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nasus Pharma's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Nasus Pharma's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $0.89 mean?
Nasus Pharma (NSRX) has a Net-Net Working Capital of $0.89 as of Jun. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Nasus Pharma According to the industry distribution chart, Nasus Pharma ranks #124 out of 393 companies in the Drug Manufacturers industry, placing it in the top 31.6%.
Is Nasus Pharma's Net-Net Working Capital too high?
Nasus Pharma's current Net-Net Working Capital is $0.89. The Drug Manufacturers industry median Net-Net Working Capital is 8.18. Nasus Pharma's value of $0.89 is 89.1% below this industry median. Based on the distribution chart, Nasus Pharma ranks #124 out of 393 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Nasus Pharma has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Nasus Pharma's Net-Net Working Capital compare to MIRA and SCLX?
According to the Drug Manufacturers industry distribution chart, Nasus Pharma ranks #124 out of 393 companies for Net-Net Working Capital. This puts Nasus Pharma in the upper half of its industry. The industry median Net-Net Working Capital is 8.18. Nasus Pharma's value of $0.89 is 89.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Drug Manufacturers company?
The median Net-Net Working Capital among Drug Manufacturers companies is 8.18, based on 393 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nasus Pharma's current Net-Net Working Capital of $0.89 is 89.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Nasus Pharma For the Drug Manufacturers industry, the median Net-Net Working Capital is 8.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nasus Pharma's current Net-Net Working Capital is $0.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nasus Pharma stock overvalued right now?
Nasus Pharma (NSRX) has a current Net-Net Working Capital of $0.89. The current Net-Net Working Capital is $0.89 and 89.1% below the Drug Manufacturers industry median of 8.18. Nasus Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Nasus Pharma (NSRX), the current Net-Net Working Capital is $0.89 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
14GF Score
Get the complete analysis for NSRX
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSRX has been successfully added to your 
